Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Schlumberger, Martin; Tahara, Makoto; J. Wirth, Lori; Robinson, Bruce; S. Brose, Marcia; Elisei, Rossella; Amir Habra, Mouhammed; Newbold, Kate; H. Shah, Manisha; O. Hoff, Ana; G. Gianoukakis, Andrew; Kiyota, Naomi; H. Taylor, Matthew; Kim, Sung‐Bae; K. Krzyzanowska, Monika; E. Dutcus, Corina; de las Heras, Begoña; Zhu, Junming; I. Sherman, Steven

doi:10.1056/nejmoa1406470

Public

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Published in New England Journal of Medicine • Feb 11, 2015

Authors:

Martin Schlumberger

Makoto Tahara

Lori J. Wirth

Abstract

BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid c...

Subject

Lenvatinib

Medicine

Refractory (planetary science)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!